Electromagnetic stimulation (EMS) has been suggested in the past as a treatment for men with CP/CPPS, particularly for those who did not respond to pharmacotherapy. Thirty-seven of 46 men with CP/CPPS who underwent electromagnetic stimulation were available for analysis. With very few adverse events (AEs), three-quarters of the patients who completed therapy reported a positive answer to benefit. Sixty percent had perceptible improvement based on the decrease of the CP symptom index score. This study did suggest that EMS

may be a reasonable treatment option for CP/CPPS patients who Inhibitors,research,lifescience,medical do not respond to drug therapy.29 Pelvic muscle tenderness is frequent in patients with CP/CPPS and Inhibitors,research,lifescience,medical previous reports from the AUA suggest that pelvic myofascial physical therapy is helpful. A unique and innovative internal therapeutic trigger point wand, which allows patients self-treatment, was investigated in 113 of 169 patients who completed 6 months of use. This curved wand serves as an extended finger to locate and release painful myofascial trigger selleck chemical JQ1 points and incorporates an integrated algometer sensor to monitor point pressure

Inhibitors,research,lifescience,medical and prevent excessive or dangerous force. There were no serious side effects and rare transient episodes of mucosal bleeding. The majority of patients who completed 6 months of therapy indicated that they were very satisfied or moderately satisfied with the use of the wand. This self-treatment utilizing a therapeutic wand for myofascial trigger point release appears to be a safe and viable CPPS management option.30 Nerve growth factor (NGF) levels Inhibitors,research,lifescience,medical correlate with pain severity

in CP/CPPS. Tanezumab, a humanized monoclonal antibody, selectively inhibits Inhibitors,research,lifescience,medical NGF. Safety and efficacy (pain and symptoms) of tanezumab were assessed in a double-blind, randomized, placebo-controlled proof of concept study. Overall, 62 patients with CP/CPPS were randomized to receive active treatment or placebo. At week 6, tanezumab marginally improved average daily pain and urgency and episodes of frequency versus placebo, but this was not statistically proven. Eighty percent of tanezumab versus 65.6% of placebo patients experienced an AE with paresthesia Drug_discovery being the most common AE in the tanezumab group (26.7% vs 6.3% in the placebo group). This exploratory study suggests that tanezumab might provide some symptom improvement compared with placebo for patients with CP/CPPS; however, it does not appear to provide significant benefit for an unselected CP/CPPS population. These findings support additional efforts to define which patient phenotypes may prove amenable to NGF-directed therapy.31 Over the years, a number of trials evaluating alpha-blockers have been presented at the AUA, with variable results.